PDCD1 and urinary bladder carcinoma: In the same year, three other phase I clinical trials were started, evaluating PD-1-KO primary T-cells in Stage IV bladder cancer (NCT02863913), metastatic renal cell carcinoma (NCT02867332), and hormone-refractory prostate cancer (NCT02867345), all of which were later withdrawn.